Open Biopharma' s goal is to drive innovation that reduces the cost of developing and manufacturing biopharmaceuticals, especially CGT, provide industry-ready workforce, a robust regional talent pipeline and GxP community resources. The Institute will also support non-viral delivery technologies for proteins, CGT.

Fundraising strategy and scaling support for innovative life science companies in US and globally wth a focus on Therapeutic and Diagnostic Platforms and Precision Medicine.

Recognized as the 2022 Top Emerging Company by BIO International, SiVEC Biotechnologies has developed BactPac™, a live biotherapeutic delivery platform to enable the next generation of nucleic acid and gene editing therapies. SiVEC’s BactPac platform is engineered to produce and safely deliver large and structured therapeutic payloads (mRNA, siRNA, proteins/nanobodies, and CRISPR/Cas) to a wide range of targeted tissues that cannot be targeted by viral vectors, lipid nanoparticles, exosomes and… Show more Recognized as the 2022 Top Emerging Company by BIO International, SiVEC Biotechnologies has developed BactPac™, a live biotherapeutic delivery platform to enable the next generation of nucleic acid and gene editing therapies. SiVEC’s BactPac platform is engineered to produce and safely deliver large and structured therapeutic payloads (mRNA, siRNA, proteins/nanobodies, and CRISPR/Cas) to a wide range of targeted tissues that cannot be targeted by viral vectors, lipid nanoparticles, exosomes and other delivery systems. SiVEC’s mission is to use BactPac to develop first-in-class therapeutics targeting cancer, respiratory, and genetic diseases and out-license the BactPac to companies who need a safe, tissue-targeted method of delivery to advance nucleic acid and gene therapies into clinical stages. Show less

Gates Grubstake Fund investment decisions are made on a competitive basis by a Scientific Investment Advisory Committee (SIAC). The SIAC is comprised of a diverse group of subject matter experts and institutional investors with a focus on biotechnology — all dedicated to moving the needle toward commercialization and patient treatment.

CLS Innovation & Entrepreneurship Mission is to be a catalyst for life sciences innovation, bolster our CA community, and help entrepreneurs build successful ventures by offering advisory, complementary programs and access to capital to first-time founders with early-stage innovative, transformational projects.

CrowdSmart is a pioneer in the application of prediction science for early-stage startup investing, combining world-class artificial intelligence (AI) and a diverse global community of Member Evaluators to democratize the seed-investing ecosystem and deliver better outcomes for investors and entrepreneurs alike. Focus is on Tech and Health IT. The solution is over 80% accurate at predicting early-stage startup funding success. About 40% of the funded start-ups have women co-founders or women in… Show more CrowdSmart is a pioneer in the application of prediction science for early-stage startup investing, combining world-class artificial intelligence (AI) and a diverse global community of Member Evaluators to democratize the seed-investing ecosystem and deliver better outcomes for investors and entrepreneurs alike. Focus is on Tech and Health IT. The solution is over 80% accurate at predicting early-stage startup funding success. About 40% of the funded start-ups have women co-founders or women in C-Level positions.In 2019 CrowdSmart's founded a diversified Member Advisory Board which is made up of experienced investors, founders and domain experts to help the executive team to understand the motivations and needs of the members.https://crowdsmart.io/ Show less

Richtr Financial Studio (RFS) works primarily with innovative founders and companies from start-up to exit. RFS niche expertise is in the following areas:1. Grant accounting & grant compliance;2. Positioning for Capital - preparation of Seed or series A round,3. Post-funding support: KPI dashboards and board/investor communication;4. Fractional CFO service if company has no CFO yet.

Fundraising and Business Development Strategies and Services for Therapeutics, Diagnostics, Medical Devices:1. Offering Corporate Business Development Services to diagnostic, therapeutic and technology companies in fund raising mode to accelerate time to funding success- by helping to prepare a 60 second pitch/elevator pitch, Exec Summary and slide deck;- by targeting specific investors interested in your field; selecting right lead investors- by finding alternative or adjunct… Show more Fundraising and Business Development Strategies and Services for Therapeutics, Diagnostics, Medical Devices:1. Offering Corporate Business Development Services to diagnostic, therapeutic and technology companies in fund raising mode to accelerate time to funding success- by helping to prepare a 60 second pitch/elevator pitch, Exec Summary and slide deck;- by targeting specific investors interested in your field; selecting right lead investors- by finding alternative or adjunct funding sources through licensing strategies;- by enhancing the value proposition through R&D co-operations with industry.Contracted by Life Science Companies like Cascade Biosystems Inc. to support and advice on fundraising efforts.2. Offering New Business Development Services and Sales Strategies to Software-as-a-Service providers and Medical Device Companies:- Lead generation through a diversified digital sales strategy using 5 tools.- Relationship building through quality conversations with prospects and clients.Currently contracted by RBP Software to accelerate market penetration for the guest facing post-stay inquiry solution for the hotel industry. Show less

After 10 years of successfully developing leads and generating IP for clients, BioBlocks has identified a combination of factors that can light the way to substantially better candidates for preclinical optimization. BioBlocks has developed an innovative proprietary Drug Discovery Platform called Leap-to-Lead™ .Leap-to-Lead™ Platform will enable scientific researchers who found a new target for example in cancer or CNS to discover "first-in-class" small molecules with substantially better… Show more After 10 years of successfully developing leads and generating IP for clients, BioBlocks has identified a combination of factors that can light the way to substantially better candidates for preclinical optimization. BioBlocks has developed an innovative proprietary Drug Discovery Platform called Leap-to-Lead™ .Leap-to-Lead™ Platform will enable scientific researchers who found a new target for example in cancer or CNS to discover "first-in-class" small molecules with substantially better properties and potentially higher success rate to reach IND.The Platform is based on BioBlocks - proprietary Comprehensive Fragment Library (CFL) - a next generation 3D Fragment Library- and Syntheverse™ - reaction-based access to currently synthesizable compoundsOpportunities for Research Collaboration:BioBlocks is seeking partnerships with companies that have complementary capabilities in target screening and requisite biology. These collaborations would have the capacity to create drug candidates drawing on BioBlocks’ proprietary chemical space, the processes of its platform and its partners’ depth of experience in target biology. BioBlocks is open to various options for collaboration such as:- Jointly developing a lead series- Identifying and accomplishing project milestones- Utilizing Leap-to-Lead™ to develop a pipeline with multiple targets Show less

Arisan Therapeutics' mission is the discovery and development of solutions for the prophylaxis, diagnosis and treatment of neglected and emerging infectious diseases including viral hemorrhagic fevers. Arisan has two preclinical programs for the development of novel oral, small molecule prophylactics / therapeutics for broad-spectrum Ebola (EBOV, SUDV and BDBV) and arenaviruses (Lassa, Junin and other new world viruses) infection. In both programs we have identified lead candidates… Show more Arisan Therapeutics' mission is the discovery and development of solutions for the prophylaxis, diagnosis and treatment of neglected and emerging infectious diseases including viral hemorrhagic fevers. Arisan has two preclinical programs for the development of novel oral, small molecule prophylactics / therapeutics for broad-spectrum Ebola (EBOV, SUDV and BDBV) and arenaviruses (Lassa, Junin and other new world viruses) infection. In both programs we have identified lead candidates with broad-spectrum activity and drug-like properties including oral bioavailability.To complement the therapeutic R&D efforts, Arisan is further developing an infectious disease point-of-care (POC) diagnostic platform in collaboration with a partner with current focus on Ebola, Lassa, Zika and Dengue.Arisan's vision is to combine convenient and highly-sensitive diagnostics with effective prophylactic and/or therapeutic treatments to provide an optimal defense against emerging and re-emerging infectious diseases globally.Arisan has been successful in securing non-dilutive funding through SBIR grants to drive programs internally and is constantly seeking new funding sources to accelerate the development of lead compounds. Show less

Forentis www.forentis.com is a special purpose venture fund in the business of saving livesand returning reason to the pharmaceutical and diagnostic industries.Here is the press release for more information on the fund for investors and other interested parties:

Providing a positive guest experience is the main priority for hoteliers. Research has shown that 20%-25% of guests will have inquiries or billing dispute after check out. Resolving the 'Post Stay'​ issues in a timely manner leaves a lasting impression of their total experience. RBP Software Solutions has developed a 'Guest Facing'​ Solution for resolving post stay inquiries and disputes. The cloud based environment allows on-line communication with guest 's… Show more Providing a positive guest experience is the main priority for hoteliers. Research has shown that 20%-25% of guests will have inquiries or billing dispute after check out. Resolving the 'Post Stay'​ issues in a timely manner leaves a lasting impression of their total experience. RBP Software Solutions has developed a 'Guest Facing'​ Solution for resolving post stay inquiries and disputes. The cloud based environment allows on-line communication with guest 's. RBP's automated solution tracks, monitors and controls all inquiries/disputes. The Company has partnered with Starwood Hotels Worldwide to implement the solution at individual properties. Currently RBP has over 65 system users. Contact me to schedule an online demo at sibylle@rbpsoftwaresolutions.com ! Show less

Identified, developed, assessed and tracked partnering and funding opportunities. Articulated the value proposition to assay development partners and potential investors.Formulated Business Development Strategy, reviewed strategic plan and investor presentation and issued recommendations to enhance value proposition.Generated 4 leads with executive team at Bio 2014 and helped to negotiate and close assay development deal with a leading US Laboratory.

Transworld Accelerator and Transworld Profit Recovery are unique cloud based software products helping businesses and healthcare providers (medical, dental, veterinarians) to increase in-house collection rate while saving cost and time. In addition the system insures absolute compliance with all regulations and collection laws. Interfaces with many different Practice Management Software, QuickBooks and other accounting software make it the leading solution in the industry.Build client base… Show more Transworld Accelerator and Transworld Profit Recovery are unique cloud based software products helping businesses and healthcare providers (medical, dental, veterinarians) to increase in-house collection rate while saving cost and time. In addition the system insures absolute compliance with all regulations and collection laws. Interfaces with many different Practice Management Software, QuickBooks and other accounting software make it the leading solution in the industry.Build client base from scratch by generating new leads and acquiring new clients through a mix of cold calling activities, conducting educational webinars, as well as through partnerships with medical, dental and veterinarian associations. Achieved high renewal rate through exceptional customer relationship management. Show less

Developed business plan and implementation strategy for a new business segment resulting in acquisition of small manufacturing plant in the US. More than tripled contracted manufacturing volume of one of the top key accounts by anticipating a shift in market demand and by building trust with the strategic account in contract manufacturers capabilities to deliver.

Negotiated agreements for research co-operations with academia and research institutes, orchestrated business plan, prepared and participated in presentations to investors for round C financing. Responsible for coordinating the due diligence.

Orchestrated business plan and presentations to European Venture Capital Funds. Lead search for lab and office space in Germany.

Held several management positions within the multinational corporation Boehringer Mannheim which was acquired by Roche in 1997:Strategic Planning, International Marketing, Business Development, Licensing including special projects requiring relocation to Singapore and US.